Pelthos Therapeutics Inc. (PTHS) - What Are Analysts Saying About This Stock?

Key Points

• Analyst consensus is “Moderate Buy”: Six of seven analysts rate Pelthos Therapeutics a buy, while one recommends selling. The average 12-month price target is $52.83, although several firms recently lowered their targets.
• The stock trades well below analyst targets: PTHS opened at $20.15, compared with a 52-week range of $18.19 to $37.50. The company reported a quarterly loss of $6.62 per share, negative margins and return on equity, and analysts expect a full-year loss of $15.22 per share.
• Pelthos is a high-risk clinical-stage biotech: The company is developing non-opioid pain treatments that remain subject to clinical testing and regulatory approval. Institutional investors own nearly 78% of the stock, and its beta of 3.07 indicates substantial volatility.

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $52.83.

A number of analysts recently weighed in on PTHS shares. Lake Street Capital decreased their price target on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, October 12th. Zacks Research lowered Pelthos Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 7th. Finally, Oppenheimer reduced their price objective on Pelthos Therapeutics from $66.00 to $64.00 and set an "outperform" rating on the stock in a research note on Friday, August 14th.

Pelthos Therapeutics Price Performance

Pelthos Therapeutics stock opened at $20.15 on Friday. Pelthos Therapeutics has a 52-week low of $18.19 and a 52-week high of $37.50. The firm has a fifty day moving average of $23.45 and a 200-day moving average of $25.07. The firm has a market capitalization of $77.17 million, a P/E ratio of -0.92 and a beta of 3.07. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The business had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. As a group, analysts predict that Pelthos Therapeutics will post -15.22 EPS for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE raised its position in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Free Report) by 59.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,919 shares of the company's stock after acquiring an additional 4,819 shares during the quarter. Pale Fire Capital SE owned 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent quarter. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Company Profile

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company's work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company's specific product pipeline, operating history, geographic reach and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.